Skip to content
Open access · OA via OpenAlex

PD-1 and PD-1 ligands: from discovery to clinical application

Taku Okazaki, T Honjo

International Immunology · 2007 · ▲ 1,286 citations

Abstract

Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/intimm/dxm057
Canonical
link ↗
Fetched
2026-06-07 MST

Cite this

APA
Okazaki, T., &amp; Honjo, T. (2007). PD-1 and PD-1 ligands: from discovery to clinical application. <em>International Immunology</em>. https://doi.org/10.1093/intimm/dxm057
Vancouver
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology. 2007. doi:10.1093/intimm/dxm057.
BibTeX
@article{taku2007PDandP, title = {PD-1 and PD-1 ligands: from discovery to clinical application}, author = {Taku Okazaki and T Honjo}, journal = {International Immunology}, year = {2007}, doi = {10.1093/intimm/dxm057}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings